Last reviewed · How we verify
NCT04006353
The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects
Phase 4 trial testing ABT in Drug Interaction in 24 participants. Completed in 3 December 2019.
30 September 2019
Quick facts
| Lead sponsor | Shanghai Public Health Clinical Center |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 11 July 2019 |
| Primary completion | 30 September 2019 |
| Estimated completion | 3 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
Conditions studied
- Drug Interaction — all drugs for Drug Interaction →
Sponsor
Shanghai Public Health Clinical Center
Who can join
Adults 18 to 65, any sex, with Drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to estimate the drug interaction between RIF and ABT. This will be a single-center, open-label, parallel study in healthy adult subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04006353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug Interaction
Currently open trials in the same condition.
- NCT06717581 — Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older. · recruiting
- NCT05512169 — Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia · recruiting
- NCT04593680 — Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for P · NA · active not recruiting
- NCT04590417 — Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomit · NA · active not recruiting
Other Shanghai Public Health Clinical Center trials
Trials by the same sponsor.
- NCT07526363 — Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections · not yet recruiting
- NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
- NCT06926569 — Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis · NA · not yet recruiting
- NCT06768697 — Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant · EARLY_PHASE1 · not yet recruiting
- NCT05129189 — Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04006353 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Public Health Clinical Center
- Last refreshed: 24 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04006353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing